U.S. court denies Jazz Pharma bid to revive patents on narcolepsy drug

(Reuters) – A U.S.
appeals court on Friday ruled invalid patents owned by Jazz Pharmaceuticals PLC covering its narcolepsy drug Xyrem, opening the door for Amneal Pharmaceuticals Inc to launch a generic version of the medicine. The U.
S. Court of Appeals for the Federal Circuit affirmed a series of rulings in favor of Amneal that the Jazz patents described obvious ideas.
Jazz and Amneal did not immediately respond to requests for comment. Shares of Jazz fell 2.
5 percent to $175 in morning trading, while Amneal was up 1 percent to $18.50.
Amneal had asked an administrative court run by the U.S.
Patent and Trademark Office to cancel the patents in hopes of bringing a generic version of Xyrem to market. The patent tribunal sided with Amneal in 2016, prompting an appeal by Jazz.
Xyrem generated more than $1.1 billion in sales in 2017, accounting for about 70 percent of Jazz’s revenue.
Xyrem is an approved treatment for both excessive daytime sleepiness and cataplexy in patients with narcolepsy, a chronic neurological disorder. .


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: